02:50 PM EST, 11/11/2024 (MT Newswires) -- US benchmark equity indexes were mixed after midday Monday as traders awaited key inflation data and corporate earnings due later this week.

The Dow Jones Industrial Average was up 0.8% at 44,318.1 intraday, while the S&P 500 rose 0.1% to 6,001.1. The Nasdaq Composite fell 0.1% to 19,278.2. Among sectors, consumer discretionary and financials led the gainers, while technology saw the biggest drop.

Official data are expected to show Wednesday that US consumer inflation rose 0.2% sequentially and 2.4% annually in October, according to a Bloomberg-compiled consensus.

Core inflation, which excludes the volatile food and energy components, is seen accelerating 0.3%, Morgan Stanley said in a note e-mailed Monday. "However, we think the strength is in large part just short-run noise (amid a) temporary acceleration in cars due to the recent hurricanes and short-lived payback in shelter after the weak print in September."

Official producer prices data for last month are scheduled to be released Thursday.

Home Depot ( HD ) , Cisco ( CSCO ) , Walt Disney ( DIS ) and AstraZeneca ( AZN ) are among the companies scheduled to report their latest quarterly financial results later in the week. Live Nation Entertainment ( LYV ) and Grab (GRAB) are slated to post results after Monday's closing bell.

In company news, Tesla (TSLA) shares were up 8.2% intraday, among the best performers on the S&P 500 and the Nasdaq. The electric vehicle maker's artificial intelligence opportunity will likely get fast tracked under the incoming Donald Trump administration, Wedbush Securities said in a note to clients.

Cigna Group ( CI ) shares jumped 7.8%, among the top S&P 500 gainers, after the health insurer said it is not pursuing a combination with Humana (HUM) and is on track to meet its full-year earnings target. Humana shares were down 1.8%.

Salesforce ( CRM ) was the top gainer on the Dow, up 5.3%, as Jefferies adjusted its price target on the stock to $400 from $350 while maintaining its buy rating.

AbbVie ( ABBV ) said its two phase 2 trials assessing emraclidine in adult patients with schizophrenia and acute exacerbation of psychotic symptoms didn't meet their primary goals. The company's shares were down nearly 12%, the second-steepest decline on the S&P 500.

Celanese (CE) shares dropped 6.6%, among the worst performers on the S&P 500, amid rating downgrades at UBS and BMO Capital.

West Texas Intermediate crude oil fell 3.1% to $68.17 a barrel intraday. Prices dropped as the threat of a supply disruption from storm Rafael in the US Gulf of Mexico eased, while China's recent stimulus plan disappointed investors, Reuters reported.

Gold was down 2.6% at $2,625.80 per troy ounce, while silver lost 2.3% to $30.72 per ounce.